Leta i den här bloggen

onsdag 17 juli 2019

Tarkka gluteenittoman dieetin pitäminen vähentää malignisoitumisen riskejä.

https://www.gastrojournal.org/article/S0016-5085(05)00196-4/fulltext?referrer=https%3A%2F%2Fbmcgastroenterol.biomedcentral.com%2Farticles%2F10.1186%2Fs12876-018-0926-4

Association of celiac disease and intestinal lymphomas and other cancers
Carlo Catassi ,Italo Bearzi, Geoffrey K.T. Holmes

Celiac disease (CD) is associated with intestinal lymphoma and other forms of cancer, especially adenocarcinoma of the small intestine, of the pharynx, and of the esophagus. Enteropathy-associated T-cell lymphoma (EATL) is a rare form of high-grade, T-cell non-Hodgkin lymphoma (NHL) of the upper small intestine that is specifically associated with CD. This NHL subtype arises in patients with either previously or concomitantly diagnosed CD. In a subgroup of patients, there is progressive deterioration of a refractory form of CD. EATL derives from a clonal proliferation of intraepithelial lymphocyte s(IEL) and is often disseminated at diagnosis. Extraintestinal presentations are not uncommon in the liver/spleen, thyroid, skin, nasal sinus, and brain. The outlook of EATL is poor. Recent studies indicated that
(1) CD is associated with a significantly increased risk for NHL, especially of the T-cell type and primarily localized in the gut (EATL);
(2) the CD-lymphoma association is less common than previously thought, with a relative risk close to 3;
 (3) CD screening is not required in patients with NHL of any primary site at the onset, unless suggested by specific findings (T-cell origin and/or primary gut localization). The risk of NHL associated with clinically milder (or silent) forms could be lower than in typical cases of CD. Several follow-up studies suggest that the GFD protects from cancer development, especially if started during the first years of life. Strict adherence to the GFD seems to be the only possibility of preventing a subset of rare but very aggressive forms of cancer.


References

  1. Fairley, N.H. and Mackie, F.P. The clinical and biochemical syndrome in lymphoma and allied diseases involving the mesenteric lymph glands. BMJ. 1937; 1: 375–380
  2. Gough, K.R., Read, A.E., and Naish, J.M. Intestinal reticulosis as a complication of idiopathic steatorrhoea. Gut. 1962; 3: 232–239
  3. Holmes, G.K.T., Stokes, P.L., Sorahan, T.M., Prior, P., Waterhouse, J.A.H., and Cooke, W.T. Coeliac disease, gluten free diet and malignancy. Gut. 1976; 17: 612–619
  4. Swinson, C.M., Slavin, G., Coles, E.C., and Booth, C.C. Coeliac disease and malignancy. Lancet. 1983; 1: 111–115
  5. Logan, R.F.A., Rifkind, E.A., Turner, J.D., and Ferguson, A. Mortality in celiac disease. Gastroenterology. 1989; 97: 265–271
  6. O’Farrelly, C., Feighery, C., O’Brian, D.S., Stevens, F., Connolly, C.E., McCarthy, C. et al. Humoral response to wheat protein in patients with coeliac disease and enteropathy associated T cell lymphoma. Br Med J. 1986; 293: 908–910
    • View in Article 
    • | Crossref
    • | PubMed..  patients with enteropathy associated T cell lymphoma do not display a humoral immune response to wheat protein (alpha gliadin), rarely respond to a gluten free diet, and are often men. Patients with uncomplicated coeliac disease usually have raised levels of alpha gliadin antibody, always respond to a gluten free diet, and are frequently women. These findings suggest the presence of two separate forms of enteropathy: one is benign and sensitive to wheat protein whereas the other runs a malignant course.
    • | Scopus (106)
      • |
    • Google Scholar
  7. Leonard, J.N., Tucker, W.F., Fry, J.S., Coulter, C.A., Boylston, A.W., McMinn, R.M. et al. Increased incidence of malignancy in dermatitis herpetiformis. Br Med J. 1983; 286: 16–18
  8. Sigurgeirsson, B., Agnarsson, B., and Lindelof, B. Risk of lymphoma in patients with dermatitis herpetiformis. Br Med J. 1994; 308: 13–15
  9. Holmes, G.K.T., Prior, P., Lane, M.R., Pope, D., and Allan, R.N. Malignancy in celiac disease. Effect of a gluten-free diet. Gut. 1989; 30: 333–338
  10. Fasano, A. and Catassi, C. Current approaches to diagnosis and treatment of celiac disease (an evolving spectrum) . Gastroenterology. 2001; 120: 636–651
  11. Chiu, B.C. and Weisenburger, D.D. An update of the epidemiology of non-Hodgkin lymphoma. Clin Lymphoma. 2003; 4: 161–168
  12. Schweizer, J., Oren, A., Mearin, M.L., and Working Group for Celiac Disease and Malignancy of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2001; 33: 97–100
  13. Howdle, P.D., Jalal, P.K., Holmes, G.K.T., and Houlston, R.S. Primary small-bowel malignancy in the UK and its association with coeliac disease. Q J Med. 2003; 96: 345–353
  14. Egan, L.J., Walsh, S.V., Stevens, F.M., Connolly, C.G., Egan, E.L., and McCarthy, C. Coeliac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era. J Clin Gastroenterol. 1995; 21: 123–129
  15. Meijer, J.W.R., Mulder, C.J.J., Goerres, M.G., Boot, H., and Schweizer, J.J. Coeliac disease and (extra)intestinal T-cell lymphomas (definition, diagnosis and treatment) . Scand J Gastroenterol Suppl. 2004; 241: 78–84
  16. Bagdi, E., Diss, T.C., Munson, P., and Isaacson, P.G. Mucosal intra-epithelial lymphocytes in enteropathy-associated T-cell lymphoma, ulcerative jejunitis, and refractory celiac disease constitute a neoplastic population. Blood. 1999; 94: 260–264
  17. Cellier, C., Delabesse, E., Helmer, C., Patey, N., Matuchansky, C., Jabri, B. et al. Refractory sprue, celiac disease, and enteropathy-associated T-cell lymphoma. Lancet. 2000; 356: 203–208
  18. Patey, N., Cellier, C., Jabri, B., Delabesse, E., Verkarre, V., Roche, B. et al. Distinction between coeliac disease and refractory sprue (a simple immunohistochemical method) . Histopathology. 2000; 37: 70–77
    • View in Article 
    • | Crossref
    • | PubMed
      We recently showed that refractory sprue is distinct from coeliac disease, the former being characterized by abnormal intraepithelial T-lymphocytes expressing a cytoplasmic CD3 chain (CD3c), lacking CD3 and CD8 surface expression, and showing TCRgamma gene rearrangements. To take advantage of the abnormal phenotype of CD3c + CD8 - intraepithelial lymphocytes (IEL) in refractory sprue we developed a simple method to distinguish coeliac disease from refractory sprue.Comparative immunohistochemical studies using anti-CD3 and anti-CD8 antibodies were applied on paraffin-embedded and frozen biopsy specimens in refractory sprue (n = 6), coeliac disease (n = 10), healthy controls (n = 5) and suspected refractory sprue (n = 6). Comparable results were obtained on fixed and frozen biopsy specimens. In four of the six patients with suspected refractory sprue, abnormal CD3c + CD8 - IEL and TCRgamma gene rearrangements were found, as in refractory sprue; the remaining two patients had normal (CD3 + CD8 +) IEL and no TCRgamma gene rearrangements. Both patients had coeliac disease, as one failed to comply with a gluten-free diet, while the other was a slow responder.This simplified immunostaining method using anti-CD3 and anti-CD8 antibodies on paraffin sections can distinguish active coeliac disease from refractory sprue and should prove useful in clinical practice.
    • | Scopus (96)
      • |
    • Google Scholar
  19. Rampertab, S.D., Fleischauer, A., Neugut, A.I., and Green, P.H. Risk of duodenal adenoma in celiac disease. Scand J Gastroenterol. 2003; 38: 831–833
  20. Johnston, S.D. and Watson, R.G. Small-bowel lymphoma associated with unrecognised celiac disease. Eur J Gastroenterol Hepatol. 2000; 12: 645–648
  21. Harris, O.D., Cooke, W.T., Thompson, H., and Waterhouse, J.A. Malignancy in adult coeliac disease and idiopathic steatorrhoea. Am J Med. 1967; 42: 899–912
    • View in Article 
    • | Abstract From a review of 202 patients with adult coeliac disease (ACD) or idiopathic steatorrhoea (IS) evidence is given that both of these disorders can be complicated by malignancy, either lymphoma or carcinoma of the gastrointestinal tract (especially of the oesophagus). The incidence is highly significant in men, and significant in women. The mean duration of symptoms of coeliac disease prior to the diagnosis of lymphoma was 21.2 years, and of carcinoma of the gastrointestinal tract 38.5 years. A gluten-free diet appeared to decrease the risk of malignant complication.
    • | Full Text PDF
    • | PubMed
    • | Scopus (275)
      • |
    • Google Scholar
  22. Selby, W.S. and Gallagher, N.D. Malignancy in a 19-year experience of adult celiac disease. Dig Dis Sci. 1979; 24: 684–688
  23. Askling, J., Linet, M., Gridley, G., Halstensen, T.S., Ekstrom, K., and Ekbom, A. Cancer incidence in a population-based cohort of individuals hospitalised with celiac disease or dermatitis herpetiformis. Gastroenterology. 2002; 123: 1428–1435
  24. Freeman, H.J. Lymphoproliferative and intestinal malignancies in 214 patients with biopsy-defined celiac disease. J Clin Gastroenterol. 2004; 38: 429–434
  25. Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K., Cleary, M.L. et al. A revised European-American classification of lymphoid neoplasms (a proposal from the International Lymphoma Study Group) . Blood. 1994; 84: 1361–1392
  26. O’Connor, T.M., Cronin, C.C., Loane, J.F., O’Meara, N.M., Firth, R.G., Sanan, F. et al. Type 1 diabetes mellitus, celiac disease, and lymphoma (a report of four cases) . Diabet Med. 1999; 16: 614–617
  27. Bleiberg, H., Duchateau, J., N’Koua M’Bon, J.B., Gerard, B., Bron, D., Debusser, L. et al. Increased incidence of lymphomas and carcinomas in patients with celiac disease. Eur J Cancer. 1998; 34: 592–593
  28. Card, T.R., West, J., and Holmes, G.K.T. Risk of malignancy in diagnosed coeliac disease (a 24-year prospective, population-based cohort study) . Aliment Pharmacol Ther. 2004; 20: 769–775
  29. West, J., Logan, R.F.A., Hill, P.G., Lloyd, A., Lewis, S., Hubbard, R. et al. Seroprevalence, correlates, and characteristics of undetected coeliac disease in England. Gut. 2003; 52: 960–965
  30. Snook, J.A., Dwyer, L., Lee-Elliott, C., Khan, S., Wheeler, D.W., and Nicholas, D.S. Adult coeliac disease and cigarette smoking. Gut. 1996; 39: 60–62
  31. Green, P.H., Fleischauer, A.T., Bhagat, G. et al. Risk of malignancy in patients with celiac disease. Am J Med. 2003; 115: 191–195
  32. Verkarre, V., Romana, S.P., Cellier, C., Asnafi, V., Mention, J.J., Barbe, U. et al. Recurrent partial trisomy 1q22-q44 in clonal intraepithelial lymphocytes in refractory celiac sprue. Gastroenterology. 2003; 125: 40–46
  33. Obermann, E.C., Diss, T.C., Hamoudi, R.A., Munson, P., Wilkins, B.S., Camozzi, M.L. et al. Loss of heterozygosity at chromosome 9p21 is a frequent finding in enteropathy-type T-cell lymphoma. J Pathol. 2004; 202: 252–262
  34. Peters, U., Askling, J., Gridley, G., Ekbom, A., and Linet, M. Causes of death in patients with celiac disease in a population-based Swedish cohort. Arch Intern Med. 2003; 163: 1566–1572
  35. Corrao, G., Corazza, G.R., Bagnardi, V., Brusco, G., Ciacci, C., Cottone, M. et al. Mortality in patients with coeliac disease and their relatives (a cohort study) . Lancet. 2001; 358: 356–361
  36. Catassi, C., Fabiani, E., Corrao, G., Barbato, M., De Renzo, A., Carella, A.M. et al. Risk of non-Hodgkin lymphoma in celiac disease. JAMA. 2002; 287: 1413–1419
  37. Mearin, M.L. Results of the European multicenter study on celiac disease and non-Hodgkin lymphoma (Proceedings of the Xth International Symposium on celiac disease) . in: John Libbey Eurotext, Montrouge, France; 2003: 225–227
  38. Farré, C., Domingo-Domenech, E., Font, R., Marques, T., De Sevilla, A.F., Alvaro, T. et al. Celiac disease and lymphoma risk (a multicentre case-control study in Spain) . Dig Dis Sci. 2004; 49: 408–412
  39. Loftus, C.G. and Loftus, E.V. Cancer risk in celiac disease. Gastroenterology. 2004; 123: 1726–1729
  40. Collin, P., Reunala, T., Pukkala, E., Laippala, P., Keyrilainen, O., and Pasternack, A. Coeliac disease-associated disorders and survival. Gut. 1994; 35: 1215–1218
 
Upplagd av kl. 1 kommentar:
Etiketter:
Prenumerera på: Inlägg (Atom)